Vanda Pharmaceuticals Inc (VNDA) (Q3 2026) Earnings Call Highlights: Revenue Jumps 24% as ...
Vanda Pharmaceuticals Inc (VNDA) posted $69.8 million in Q3 2026 revenue on surging Fanapt demand and early Nereus sales, while narrowing its quarterly net loss ahead of key launches. Related Stocks: VNDA ,